Skip to main content
. 2018 Nov 14;2018:7426950. doi: 10.1155/2018/7426950

Figure 1.

Figure 1

Camalexin decreases viability of human leukemia cells in a dose- and time-dependent manner. (a) The chemical structure of camalexin. (b) NB4 and HL-60 cells were treated with various doses of camalexin (10 μM, 20 μM, 40 μM) for different time (24 h, 48 h, 72 h), and then cell viability was assayed by CCK-8 assay. (c) Primary leukemia cells were isolated from the peripheral blood of 3 patients and treated with various doses of camalexin (10 μM, 20 μM, 40 μM) for different time (24 h, 48 h, 72 h), and then cell viability was assayed by CCK-8 assay. (d) Mononuclear cells were isolated from the peripheral blood of 3 healthy donors and treated with different doses of camalexin (10 μM, 20 μM, 40 μM) for different time (24 h, 48 h, 72 h), and then cell viability was assayed. Mean and SD of three independent experiments performed in triplicate are shown; ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001.